@article {Nguyen2020.04.29.20084111, author = {Long H. Nguyen and David A. Drew and Amit D. Joshi and Chuan-Guo Guo and Wenjie Ma and Raaj S. Mehta and Daniel R. Sikavi and Chun-Han Lo and Sohee Kwon and Mingyang Song and Lorelei A. Mucci and Meir J. Stampfer and Walter C. Willett and A. Heather Eliassen and Jaime E. Hart and Jorge E. Chavarro and Janet W. Rich-Edwards and Christina C. Lawson and Richard Davies and Joan Capdevila Pujol and Karla A. Lee and Mary Ni Lochlainn and Thomas Varsavsky and Mark S. Graham and Carole H. Sudre and M. Jorge Cardoso and Jonathan Wolf and Sebastien Ourselin and Claire J. Steves and Tim D. Spector and Andrew T. Chan and on behalf of the COPE Consortium}, title = {Risk of symptomatic Covid-19 among frontline healthcare workers}, elocation-id = {2020.04.29.20084111}, year = {2020}, doi = {10.1101/2020.04.29.20084111}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Data are limited about severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection risk among frontline healthcare workers (HCWs) and whether personal protective equipment (PPE) mitigates this risk.Methods We performed a prospective cohort study among 2,135,190 individuals using the COVID Symptom Tracker smartphone application to collect information among frontline HCWs and the general community since March 24, 2020 (United Kingdom) and March 29, 2020 (United States). We used Cox proportional hazards modeling to estimate multivariate-adjusted hazard ratios (aHRs) of a positive Covid-19 test through April 23, 2020.Results Among 2,035,395 community individuals and 99,795 frontline HCWs, we documented 5,545 incident reports of a positive Covid-19 test over 34,435,273 person-days. Compared to the general community, frontline HCWs had an aHR of 11.6 (95\% CI: 10.9 to 12.3) for a positive test. Frontline HCWs reporting inadequate PPE availability had a 23\% increased risk of testing positive (aHR 1.23, 95\% CI: 1.03 to 1.46). Compared to HCWs reporting adequate PPE who did not care for Covid-19 patients, HCWs caring for patients with documented Covid-19 had aHRs for a positive test of 4.91 (95\% CI: 4.11 to 5.86) if they had adequate PPE and 5.94 (95\% CI: 4.57 to 7.72) if they had inadequate PPE.Conclusions Frontline HCWs had a significantly increased risk of symptomatic Covid-19 infection, which was highest among HCWs with inadequate access to PPE who cared for Covid-19 patients. However, adequate supplies of PPE did not completely mitigate high-risk exposures (ClinicalTrials.gov NCT04331509).Competing Interest StatementJW, RD, and JC are employees of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. DAD and ATC previously served as investigators on a clinical trial of diet and lifestyle using a separate mobile application that was supported by Zoe Global Ltd. Other authors have no conflict of interest to declare.Clinical TrialClinicalTrials.gov NCT04331509Funding StatementZoe provided in kind support for all aspects of building, running and supporting the tracking app and service to all users worldwide. King{\textquoteright}s College of London investigators (KAL, MNL, TV, MG, CHS, MJC, SO, CJS, TDS) were supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z, WT203148/Z/16/Z, WT213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF (MR/M016560/1), the NIHR, and the Alzheimer{\textquoteright}s Society (AS-JF-17-011). ATC is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. The National Institutes of Health grants related to this project include: UM1 CA186107 (MJS), U01 CA176726 (AHE, WCW), U01 CA167552 (WCW, LAM), U01 HL145386 (JEC), R24 ES028521 (JEC), P30ES000002 (JEH), and a National Institute for Occupational Safety and Health grant contract 200-2017-M-94186 (JEC). An Evergrande COVID-19 Response Fund Award through the Massachusetts Consortium on Pathogen Readiness (MassCPR) supported MGH investigators (LHN, DAD, ADJ, CGG, WM, RSM, DRS, CHL, SK, MS, ATC).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected in the app is being shared with other health researchers through the NHS-funded Health Data Research U.K. (HDRUK)/SAIL consortium, housed in the U.K. Secure Research Platform (UKSeRP) in Swansea. Anonymized data is available to be shared with bonafide researchers HDRUK according to their protocols in the public interest (https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6). U.S. investigators are encouraged to coordinate data requests through the COPE Consortium (www.monganinstitute.org/cope-consortium). Data updates can be found on https://covid.joinzoe.com.}, URL = {https://www.medrxiv.org/content/early/2020/05/05/2020.04.29.20084111}, eprint = {https://www.medrxiv.org/content/early/2020/05/05/2020.04.29.20084111.full.pdf}, journal = {medRxiv} }